|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-3.84/-3.51
|
企业价值
6.51B
|
资产负债 |
每股账面净值
10.46
|
现金流量 |
现金流量率
--
|
损益表 |
收益
11.58M
|
每股收益
0.16
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 18:36 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |